What Does Your PSA Level Mean? (2026 Edition)

PSA (prostate-specific antigen) is the blood test most commonly checked first when prostate cancer is suspected. A high PSA alone isn't a diagnosis, but higher levels raise the likelihood of further testing (MRI, biopsy), and after diagnosis, PSA becomes a core indicator for determining risk group and tracking treatment response and recurrence.

Key Takeaways

• If PSA is elevated or a digital rectal exam shows abnormalities, a prostate MRI is checked first.
• PSA is not used alone — it is combined with the Gleason score (grade group) and stage to classify prostate cancer into low-risk, intermediate-risk, and high-risk groups.
• PSA remains central to follow-up after treatment: after surgery, doctors check whether it drops to an essentially undetectable level, while after radiation therapy, they watch whether it gradually declines and settles at its lowest point (nadir).
• Korea's 5-year relative survival rate for prostate cancer is 96.9% (National Cancer Registry Statistics, 2019–2023), which is explained in part by the widespread use of PSA testing leading to more cases being diagnosed at the localized stage.
• Because the rate at which PSA rises (the full history of dated values over time, not a single reading) factors into clinical decisions, it is important to keep a complete record of all past measurements.

Does a High PSA Level Mean Cancer Right Away?

• No. If PSA is elevated or a digital rectal exam is abnormal, a prostate MRI is checked first, and if the MRI shows a suspicious area, a targeted biopsy (MRI-fusion biopsy) of that specific site is performed to confirm the diagnosis.
• The Gleason score obtained from biopsy results scores how different the cancer cells are from normal tissue, using two patterns that are added together, and this is then organized into grade groups ranging from 1 to 5. A higher grade group indicates a more aggressive cancer.
• In other words, PSA level alone does not determine whether cancer is present or how severe it is — MRI, biopsy, and Gleason score are all reviewed together to make that determination.

How Is PSA Used to Decide on a Treatment Plan?

• Treatment decisions for prostate cancer are not based on stage alone. They are made using a risk group that combines PSA level, Gleason score (grade group), and stage, together with age, life expectancy, and other medical conditions.
• For example, a case with low PSA, the lowest grade group, and a small tumor confined within the prostate is classified as low-risk, for which active surveillance — monitoring without immediate treatment — is a standard option. Conversely, cases with high PSA, a high grade group, or spread beyond the prostate are classified as high-risk.
• For this reason, before reviewing treatment options in Korea, having all three pieces of information — PSA, MRI, and biopsy results (Gleason score) — ready is key material for the remote review (pre-arrival review) process.

Is PSA Still Checked After Treatment?

• Yes, PSA level remains the central measure in follow-up after treatment.
• For patients who had surgery, doctors check whether PSA drops to an essentially undetectable level. For patients who had radiation therapy, they check whether PSA gradually declines and settles at its lowest point (nadir).
• Typically, PSA is rechecked every few months during the first several years after treatment, with the interval extended once levels remain stable. If PSA rises again, imaging tests are used to locate the site of recurrence.
• Because PSA testing is widely available in most countries, it is easy to continue after returning home. A handover note listing the date of the next test and the target PSA range is typically provided for this purpose.

FAQ — Is a Single PSA Reading Enough?

No, it is not enough. Because how quickly PSA rises (the rate of increase) factors into clinical judgment, it is recommended to keep a complete record of every PSA measurement to date, along with its date. A single reading alone makes it difficult to understand the overall trend.

FAQ — During Active Surveillance, Is PSA the Only Thing That Matters?

Active surveillance is a standard option for low-risk cases, but it involves more than PSA alone — it is carried out together with MRI at set intervals and, if needed, repeat biopsy, in order to catch changes early and move to treatment at the appropriate time. This approach is only feasible if these tests can continue to be obtained consistently after returning home.

Sources and Notes

• This article was written based on the Prostate Cancer Note (National Cancer Registry Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry; NCCN Patient Guidelines; SEER 2016–2022).
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.